Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction.
暂无分享,去创建一个
[1] D. Mozaffarian,et al. Health Impact and Cost-Effectiveness of Volume, Tiered, and Absolute Sugar Content Sugar-Sweetened Beverage Tax Policies in the United States , 2020, Circulation.
[2] D. Mozaffarian,et al. Health and Economic Impacts of the National Menu Calorie Labeling Law in the United States , 2020, Circulation. Cardiovascular quality and outcomes.
[3] M. Weinstein,et al. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. , 2019, American heart journal.
[4] Francesca N. Delling,et al. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association , 2019, Circulation.
[5] E. Braunwald,et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.
[6] G. Sanders,et al. Cost-Effectiveness in Health and Medicine , 2016 .
[7] T. Trikalinos,et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.
[8] Wing W. Chan,et al. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. , 2016, JAMA cardiology.
[9] John B. Wong,et al. Decision making in health and medicine: Integrating evidence and values, second edition , 2014 .
[10] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[11] Joshua T. Cohen,et al. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.
[12] G. Fonarow,et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. , 2014, Circulation.
[13] M. Krucoff,et al. A Reevaluation of the Costs of Heart Failure and Its Implications for Allocation of Health Resources in the United States , 2014, Clinical cardiology.
[14] L. Shaw,et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.
[15] V. Roger. Epidemiology of Heart Failure , 2013, Circulation research.
[16] I. Piña,et al. Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association , 2013, Circulation. Heart failure.
[17] David Thompson,et al. Cost Estimation of Cardiovascular Disease Events in the US , 2011, PharmacoEconomics.
[18] Andrew H. Briggs,et al. Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.
[19] V. Roger,et al. Lifetime Costs of Medical Care After Heart Failure Diagnosis , 2011, Circulation. Cardiovascular quality and outcomes.
[20] Bengt Jönsson,et al. Ten arguments for a societal perspective in the economic evaluation of medical innovations , 2009, The European Journal of Health Economics.
[21] Milton C Weinstein,et al. Heart failure disease management programs: a cost-effectiveness analysis. , 2008, American heart journal.
[22] T. Gaziano,et al. Cardiovascular Disease in the Developing World and Its Cost-Effective Management , 2005, Circulation.
[23] Chris Hyde,et al. Decision Making in Health and Medicine. Integrating Evidence and Values , 2005, ACP Journal Club.
[24] M. Weinstein,et al. Decision Making in Health and Medicine , 2001 .
[25] G. Oster,et al. Cost effectiveness of carvedilol for heart failure. , 1999, The American journal of cardiology.
[26] K. Deluzio,et al. Risk Management and Healthcare Policy , 2022 .